Kingmed Diagnostics(603882) 财信证券·2024-04-30 03:00Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's revenue for 2023 was 8.54 billion yuan, a year-on-year decrease of 44.82%, with a net profit attributable to shareholders of 0.6438 billion yuan, down 76.64% year-on-year [4][6] - The decline in performance is attributed to a significant reduction in COVID-19 testing demand, increased credit impairment losses, and a slowdown in the growth of routine medical testing business [4][6] - Despite the overall decline, the routine medical testing business showed a robust growth of 15.35% year-on-year, with revenues reaching 7.73 billion yuan [4][6] - The company has developed 412 new projects in 2023, contributing 0.638 billion yuan in revenue, with notable growth in specific diagnostic areas [4][6] Financial Summary - The company's main revenue for 2022 was 15.48 billion yuan, with a net profit of 2.75 billion yuan [3][7] - For 2024, the expected revenue is 9.20 billion yuan, with a projected net profit of 0.663 billion yuan [3][7] - The earnings per share (EPS) for 2024 is estimated at 1.41 yuan, with a price-to-earnings (P/E) ratio of 26.94 [3][7] - The company’s overall gross margin decreased by 6.65 percentage points to 36.48% in 2023, influenced by industry competition and policy changes [4][6] Future Outlook - The company is expected to recover and achieve net profits of 1.06 billion yuan and 1.43 billion yuan in 2025 and 2026, respectively [6][7] - The report suggests a reasonable target price of 45.40 to 56.75 yuan per share for 2025, based on a P/E ratio of 20-25 times [6][7]